Dimidril may be available in the countries listed below.
Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Dimidril in the following countries:
International Drug Name Search
Estalex may be available in the countries listed below.
Eperisone hydrochloride (a derivative of Eperisone) is reported as an ingredient of Estalex in the following countries:
International Drug Name Search
Vitulpas may be available in the countries listed below.
Hydrocortisone 21-acetate (a derivative of Hydrocortisone) is reported as an ingredient of Vitulpas in the following countries:
International Drug Name Search
Carvedilol Arafarma Group may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carvedilol Arafarma Group in the following countries:
International Drug Name Search
Ursotamin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ketamine hydrochloride (a derivative of Ketamine) is reported as an ingredient of Ursotamin in the following countries:
International Drug Name Search
Treating patients with amyotrophic lateral sclerosis (ALS, Lou Gehrig disease) to prolong survival and/or to delay the need for surgery to help breathing (tracheostomy). It may also be used for other conditions as determined by your doctor.
Riluzole is a benzothiazole. Exactly how Riluzole works is not known. It may prevent further damage to certain brain cells (motor neurons) responsible for controlling muscle function.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Riluzole. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Riluzole. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Riluzole may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Riluzole as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Riluzole.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Abnormal skin sensations around the mouth; diarrhea; dizziness; drowsiness; headache; loss of appetite; muscle weakness; nausea; stomach pain; vomiting; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); cough, shortness of breath, or trouble breathing; fast or irregular heartbeat; frequent or painful urination; signs of infection (eg, fever, chills, sore throat); swelling of the hands or feet; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Riluzole side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Riluzole at room temperature, between 68 and 77 degrees F (20 and 25 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Riluzole out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Riluzole. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Farma 12 may be available in the countries listed below.
Benzalkonium chloride (a derivative of Benzalkonium) is reported as an ingredient of Farma 12 in the following countries:
International Drug Name Search
Vodelax may be available in the countries listed below.
Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Vodelax in the following countries:
International Drug Name Search
Naratriptan Hydrochloride may be available in the countries listed below.
Naratriptan Hydrochloride (BANM, USAN) is known as Naratriptan in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| USAN | United States Adopted Name |
Clorfeniramin may be available in the countries listed below.
Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Clorfeniramin in the following countries:
International Drug Name Search
Myconormin may be available in the countries listed below.
Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Myconormin in the following countries:
International Drug Name Search
Noscab may be available in the countries listed below.
Permethrin is reported as an ingredient of Noscab in the following countries:
International Drug Name Search
Calcium Mylan may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calcium Mylan in the following countries:
International Drug Name Search
Acido deidrocolico may be available in the countries listed below.
Acido deidrocolico (DCIT) is known as Dehydrocholic Acid in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
In some countries, this medicine may only be approved for veterinary use.
Pyrantel tartrate (a derivative of Pyrantel) is reported as an ingredient of INI Swine Ban Wormer in the following countries:
International Drug Name Search
Calcipotriolo may be available in the countries listed below.
Calcipotriolo (DCIT) is also known as Calcipotriol (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Eptavit may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Eptavit in the following countries:
Colecalciferol is reported as an ingredient of Eptavit in the following countries:
International Drug Name Search
Natrium Bicarbonicum Sintetica may be available in the countries listed below.
Sodium Bicarbonate is reported as an ingredient of Natrium Bicarbonicum Sintetica in the following countries:
International Drug Name Search
Protriptyline Hydrochloride (BANM, USAN) is known as Protriptyline in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| USAN | United States Adopted Name |
Invigen may be available in the countries listed below.
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Invigen in the following countries:
International Drug Name Search
Epitril may be available in the countries listed below.
Clonazepam is reported as an ingredient of Epitril in the following countries:
International Drug Name Search
Bat Zeta may be available in the countries listed below.
Cetylpyridinium chloride (a derivative of Cetylpyridinium) is reported as an ingredient of Bat Zeta in the following countries:
International Drug Name Search
Parutox may be available in the countries listed below.
Pantethine is reported as an ingredient of Parutox in the following countries:
International Drug Name Search
Norotyl may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Tylosin is reported as an ingredient of Norotyl in the following countries:
International Drug Name Search
Gentamicina Ranbaxy may be available in the countries listed below.
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentamicina Ranbaxy in the following countries:
International Drug Name Search
D-Histaplus may be available in the countries listed below.
Desloratadine is reported as an ingredient of D-Histaplus in the following countries:
International Drug Name Search
In the US, Sandrena is a member of the drug class estrogens and is used to treat Atrophic Urethritis, Atrophic Vaginitis, Breast Cancer - Palliative, Hypoestrogenism, Oophorectomy, Osteoporosis, Postmenopausal Symptoms, Primary Ovarian Failure and Prostate Cancer.
UK matches:
Estradiol is reported as an ingredient of Sandrena in the following countries:
Estradiol hemihydrate (a derivative of Estradiol) is reported as an ingredient of Sandrena in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Korylan may be available in the countries listed below.
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Korylan in the following countries:
Paracetamol is reported as an ingredient of Korylan in the following countries:
International Drug Name Search
Zolagel may be available in the countries listed below.
Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Zolagel in the following countries:
International Drug Name Search
Nasentropfen K Hexal may be available in the countries listed below.
Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Nasentropfen K Hexal in the following countries:
International Drug Name Search
Coranzoll may be available in the countries listed below.
Miconazole is reported as an ingredient of Coranzoll in the following countries:
International Drug Name Search
Oxacillina may be available in the countries listed below.
Oxacillina (DCIT) is known as Oxacillin in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Ci-son's may be available in the countries listed below.
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Ci-son's in the following countries:
International Drug Name Search
Diclofenac-Retard may be available in the countries listed below.
Diclofenac is reported as an ingredient of Diclofenac-Retard in the following countries:
International Drug Name Search
In the US, Invirase (saquinavir systemic) is a member of the drug class protease inhibitors and is used to treat HIV Infection and Nonoccupational Exposure.
US matches:
UK matches:
Saquinavir is reported as an ingredient of Invirase in the following countries:
Saquinavir mesilate (a derivative of Saquinavir) is reported as an ingredient of Invirase in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Neo Sampoon may be available in the countries listed below.
Menfegol is reported as an ingredient of Neo Sampoon in the following countries:
International Drug Name Search
Topiramato Milo may be available in the countries listed below.
Topiramate is reported as an ingredient of Topiramato Milo in the following countries:
International Drug Name Search
Novirax may be available in the countries listed below.
Aciclovir is reported as an ingredient of Novirax in the following countries:
International Drug Name Search
Progesterona L.CH. may be available in the countries listed below.
Progesterone is reported as an ingredient of Progesterona L.CH. in the following countries:
International Drug Name Search
Pronoctan may be available in the countries listed below.
Lormetazepam is reported as an ingredient of Pronoctan in the following countries:
International Drug Name Search
In the US, Ethionamide (ethionamide systemic) is a member of the drug class nicotinic acid derivatives and is used to treat Tuberculosis, Active.
US matches:
Rec.INN
J04AD03
0000536-33-4
C8-H10-N2-S
166
Antitubercular agent
4-Pyridinecarbothioamide, 2-ethyl-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Nematox may be available in the countries listed below.
Albendazole is reported as an ingredient of Nematox in the following countries:
International Drug Name Search
Angiozem may be available in the countries listed below.
Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Angiozem in the following countries:
International Drug Name Search
(Potency expressed as betamethasone)
*Vehicle augments the penetration of the steroid
For Dermatologic Use Only - Not for Ophthalmic Use
Rx only
Betamethasone Dipropionate Ointment (Augmented) USP, 0.05% contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone.
Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6 and the following structural formula:
Betamethasone dipropionate is a white to creamy white, odorless powder insoluble in water; freely soluble in acetone and in chloroform; sparingly soluble in alcohol.
Each gram of Betamethasone Dipropionate Ointment (Augmented) USP, 0.05% contains: 0.643 mg betamethasone dipropionate, USP (equivalent to 0.5 mg betamethasone) in an optimized vehicle of propylene glycol, USP; propylene glycol stearate; white wax, NF; and white petrolatum, USP.
The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects.
Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. (see DOSAGE AND ADMINISTRATION.)
Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. (see DOSAGE AND ADMINISTRATION.)
Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Studies performed with Betamethasone Dipropionate Ointment (Augmented) indicate that it is in the super-high range of potency as compared with other topical corticosteroids.
Betamethasone Dipropionate Ointment (Augmented) USP, 0.05% is a super-high potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older. The total dose should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Betamethasone Dipropionate Ointment (Augmented) USP, 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. (See DOSAGE AND ADMINISTRATION.)
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Patients should not be treated with amounts of Betamethasone Dipropionate Ointment (Augmented) greater than 50 g per week because of the potential for the drug to suppress HPA axis. Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppression.
At 14 g per day Betamethasone Dipropionate Ointment (Augmented) was shown to depress the plasma levels of adrenal cortical hormones following repeated application to diseased skin in patients with psoriasis. These effects were reversible upon discontinuation of treatment. At 7 g per day Betamethasone Dipropionate Ointment (Augmented) was shown to cause minimal inhibition of the HPA axis when applied 2 times daily for 2 to 3 weeks in healthy patients and in patients with psoriasis and eczematous disorders.
With 6 to 7 g of Betamethasone Dipropionate Ointment (Augmented) applied once daily for 3 weeks, no significant inhibition of the HPA axis was observed in patients with psoriasis and atopic dermatitis, as measured by plasma cortisol and 24-hour urinary 17-hydroxy-corticosteroid levels. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (see PRECAUTIONS- Pediatric Use.)
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. Betamethasone Dipropionate Ointment (Augmented) should not be used in the treatment of rosacea or perioral dermatitis, and it should not be used on the face, groin, or in the axillae.
Patients using topical corticosteroids should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
The following tests may be helpful in evaluating HPA axis suppression:
Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate. Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in-vitro, human lymphocyte chromosome aberration assay, and equivocal in the in-vivo mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone. Studies in rabbits, mice and rats using intramuscular doses up to 1, 33 and 2 mg/kg, respectively, resulted in dose related increases in fetal resorptions in rabbits and mice.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2 times the human topical dose of Betamethasone Dipropionate Ointment (Augmented) in mg/m2 of body surface area, assuming 100% absorption and the use in a 60 kg person of 7 g per day. The abnormalities observed included umbilical hernias, cephalocele and cleft palate. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Betamethasone Dipropionate Ointment (Augmented) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Betamethasone Dipropionate Ointment (Augmented) is administered to a nursing woman.
Use of Betamethasone Dipropionate Ointment (Augmented) in pediatric patients 12 years of age and younger is not recommended. (See CLINICAL PHARMACOLOGY and ADVERSE REACTIONS.)
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.
Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Chronic corticosteroid therapy may interfere with the growth and development of children.
Clinical studies of Betamethasone Dipropionate Ointment (Augmented) included 225 subjects who were 65 years of age and over and 46 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.
The local adverse reactions were reported with Betamethasone Dipropionate Ointment (Augmented) during controlled clinical trials were as follows: erythema, folliculitis, pruritus and vesiculation each occurring in less than 1% of patients.
The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (see PRECAUTIONS.)
Apply a thin film of Betamethasone Dipropionate Ointment (Augmented) USP, 0.05% to the affected skin once or twice daily. Betamethasone Dipropionate Ointment (Augmented) is a super-high potency topical corticosteroid. Treatment with Betamethasone Dipropionate Ointment (Augmented) should be limited to 50 g per week.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Betamethasone Dipropionate Ointment (Augmented) should not be used with occlusive dressings. Betamethasone Dipropionate Ointment (Augmented) should not be applied to the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
Betamethasone Dipropionate Ointment (Augmented) USP, 0.05% is supplied in 15 g (NDC 51642-1317-1) and 50 g (NDC 51672-1317-3) tubes; boxes of one; and in a 5 g physician sample (tube only).
Store at 20° - 25°C (68° - 77°F) [see USP Controlled Room Temperature].
Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1
Revised: September, 2006
LPK-4528-1
265
NDC 51672-1317-3
50 g
Betamethasone Dipropionate
Ointment (Augmented*) USP, 0.05%
(Potency expressed as betamethasone)
*Vehicle augments the penetration of the steroid.
FOR DERMATOLOGIC USE ONLY.
NOT FOR OPHTHALMIC USE.
Rx only
TARO
Keep this and all medications out of the reach of children.
| BETAMETHASONE DIPROPIONATE betamethasone dipropionate ointment, augmented | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA076753 | 10/12/2004 | |
| Labeler - Taro Pharmaceuticals U.S.A., Inc. (145186370) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Taro Pharmaceuticals Inc. | 206263295 | MANUFACTURE | |
Acix may be available in the countries listed below.
Aciclovir is reported as an ingredient of Acix in the following countries:
Aluminium Hydroxide hydrate (Algeldrate) (a derivative of Aluminium Hydroxide) is reported as an ingredient of Acix in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Zantac (ranitidine systemic) is a member of the drug class H2 antagonists and is used to treat Duodenal Ulcer, Duodenal Ulcer Prophylaxis, Erosive Esophagitis, Gastric Ulcer Maintenance Treatment, Gastrointestinal Hemorrhage, GERD, Indigestion, Pathological Hypersecretory Conditions, Stomach Ulcer, Stress Ulcer Prophylaxis, Surgical Prophylaxis and Zollinger-Ellison Syndrome.
US matches:
UK matches:
Ranitidine is reported as an ingredient of Zantac in the following countries:
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Zantac in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
In the US, Nutropin (somatropin systemic) is a member of the drug class growth hormones and is used to treat Adult Human Growth Hormone Deficiency, Growth Retardation - Chronic Renal Failure, Hypopituitarism, Idiopathic Short Stature, Pediatric Growth Hormone Deficiency, Short Stature for Age and Turner's Syndrome.
US matches:
Somatropine is reported as an ingredient of Nutropin in the following countries:
International Drug Name Search
Ramipril/HCT Actavis may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Ramipril/HCT Actavis in the following countries:
Ramipril is reported as an ingredient of Ramipril/HCT Actavis in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Narcan (naloxone systemic) is a member of the drug class antidotes and is used to treat Opioid Overdose.
US matches:
Naloxone hydrochloride (a derivative of Naloxone) is reported as an ingredient of Narcan in the following countries:
International Drug Name Search
Betahistin AL may be available in the countries listed below.
Betahistine dimesilate (a derivative of Betahistine) is reported as an ingredient of Betahistin AL in the following countries:
International Drug Name Search
Pharex Ciprofloxacin may be available in the countries listed below.
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Pharex Ciprofloxacin in the following countries:
International Drug Name Search
Taxocef may be available in the countries listed below.
Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Taxocef in the following countries:
International Drug Name Search
Sultrian may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfamethoxazole is reported as an ingredient of Sultrian in the following countries:
Trimethoprim is reported as an ingredient of Sultrian in the following countries:
International Drug Name Search
Hyopan may be available in the countries listed below.
Scopolamine butylbromide (a derivative of Scopolamine) is reported as an ingredient of Hyopan in the following countries:
International Drug Name Search
Uro Cefasabal NF may be available in the countries listed below.
Pipemidic Acid is reported as an ingredient of Uro Cefasabal NF in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Priconazole in the following countries:
International Drug Name Search
Neosynephrin-POS may be available in the countries listed below.
Phenylephrine hydrochloride (a derivative of Phenylephrine) is reported as an ingredient of Neosynephrin-POS in the following countries:
International Drug Name Search
Normovite may be available in the countries listed below.
Ferrous Glucoheptonate is reported as an ingredient of Normovite in the following countries:
Folic Acid is reported as an ingredient of Normovite in the following countries:
International Drug Name Search
Nipolept may be available in the countries listed below.
Zotepine is reported as an ingredient of Nipolept in the following countries:
International Drug Name Search
Rino naftazolina may be available in the countries listed below.
Naphazoline hydrochloride (a derivative of Naphazoline) is reported as an ingredient of Rino naftazolina in the following countries:
International Drug Name Search
Asialum may be available in the countries listed below.
Aluminium Hydroxide is reported as an ingredient of Asialum in the following countries:
Magnesium Hydroxide is reported as an ingredient of Asialum in the following countries:
International Drug Name Search
Sarinex may be available in the countries listed below.
Desloratadine is reported as an ingredient of Sarinex in the following countries:
International Drug Name Search
Noprilam may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Noprilam in the following countries:
Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Noprilam in the following countries:
International Drug Name Search
Amoxicilline Qualimed may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxicilline Qualimed in the following countries:
International Drug Name Search
Antak may be available in the countries listed below.
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Antak in the following countries:
International Drug Name Search
Corylap may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfadimethoxine sodium (a derivative of Sulfadimethoxine) is reported as an ingredient of Corylap in the following countries:
Trimethoprim is reported as an ingredient of Corylap in the following countries:
International Drug Name Search
A-Acido may be available in the countries listed below.
Tretinoin is reported as an ingredient of A-Acido in the following countries:
International Drug Name Search
DCCK may be available in the countries listed below.
Dihydroergotoxine mesilate (a derivative of Dihydroergotoxine) is reported as an ingredient of DCCK in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Ph. Eur.
A07BA
0016291-96-6
Antidote
Pharmaceutic aid
Antidiarrhoeal agent
Intestinal adsorbent
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Ph. Eur. | European Pharmacopoeia |
